BrainStorm (BCLI) Cell Therapeutics announced that it has received a delisting notification from The Nasdaq Stock Market, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm’s common stock on Nasdaq will be suspended at the open of trading on July 18. The delisting is a result of the company’s non-compliance with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement. BrainStorm has already secured approval for its common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipates its shares will begin trading on the OTCQB under the same symbol, BCLI, beginning at the open of trading on July 18, or as soon as possible thereafter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCLI:
- Brainstorm Cell Therapeutics Approves Stock Plan Amendments
- BrainStorm files to sell 2.76M shares of common stock for holders
- Promising Survival Data and Regulatory Progress Bolster Buy Rating for Brainstorm Cell Therapeutics
- BrainStorm reports new survival data from EAP for NurOwn
- Strategic Advancements and Potential of BrainStorm Cell Therapeutics: A Buy Recommendation by Jason McCarthy